In summary, in premenopausal women with ER-positive early-stage breast cancer commencing maximal estradiol suppression, treatment with denosumab prevented the increase in gynoid and android fat mass, with trends observed in preventing the increase in total fat mass and waist circumference. Here, ESR1 is linked to breast cancer.